Skip to main content
Erschienen in:

08.01.2021 | Original Article

Clinical research on the combined use of systemic chemotherapy and CT-guided radiofrequency ablation in treatment of lung cancer

verfasst von: Feng Xu, Zhigang Cai, Beizheng Xu, Jian Song, Haiyan Liu, Xuanmei Li, Aibing Deng, Xiaotang Wu, Jun Chen

Erschienen in: Lasers in Medical Science | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study is to describe the clinical efficacy and safety of the combined use of systemic chemotherapy and CT-guided radiofrequency ablation (RFA) in treatment of lung cancer. A panel of 256 patients with lung cancer who were admitted to our hospital from June 2017 to October 2019 were recruited. According to the treatment plan, the patients were divided into test group (n = 128) and control group (n = 128). Patients in the test group were treated by systemic chemotherapy combined with CT-guided RFA, while patients in the control group were given systemic chemotherapy only. After treatment, a comparative analysis was conducted in terms of clinical efficacy, level of tumor markers, and adverse reactions. Meanwhile, patients in the two groups were followed up for analysis of progression-free survival (PFS) and overall survival (OS). After treatment, the tumor objective response rate and disease control rate of patients in the test group were significantly higher than those in the control group. Besides, in patients of the test group, tumor markers, such as serum carcino-embryonic antigen, neuro-specific enolase, cytokeratin-19, and carbohydrate antigen-199, presented a remarkably lower level relative to those in the control group (p < 0.05). However, there was no significant difference observed with regard to the incidence of complications (p > 0.05). Additionally, patients in the test group were more likely to have better PFS and OS. Notably, we monitored that in the test group, superior clinical efficacy was achieved in patients with non-small cell lung cancer and lung adenocarcinoma relative to that in patients with small cell lung cancer and lung squamous cell carcinoma, respectively. The combined use of systemic chemotherapy and CT-guided RFA can produce good clinical efficacy in treatment of lung cancer. It is relatively safe and deserves promotion and application in clinic.
Literatur
7.
Zurück zum Zitat Wan Y, Sheng D, Qinghua YUJJ o. C. S. Complications of radiofrequency ablation for lung cancer:a retrospective analysis of 160 cases. (2015) Wan Y, Sheng D, Qinghua YUJJ o. C. S. Complications of radiofrequency ablation for lung cancer:a retrospective analysis of 160 cases. (2015)
8.
Zurück zum Zitat Hui LI et al (2015) CT-guided radiofrequency ablation for the treatment of advanced non-small cell lung cancer: observation of clinical short-term efficacy Hui LI et al (2015) CT-guided radiofrequency ablation for the treatment of advanced non-small cell lung cancer: observation of clinical short-term efficacy
10.
Zurück zum Zitat Therasse P et al New guidelines to evaluate the response to treatment in solid tumors. 92:205–216 Therasse P et al New guidelines to evaluate the response to treatment in solid tumors. 92:205–216
20.
Zurück zum Zitat Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T (2010) Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 30:3099–3102PubMed Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T (2010) Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 30:3099–3102PubMed
Metadaten
Titel
Clinical research on the combined use of systemic chemotherapy and CT-guided radiofrequency ablation in treatment of lung cancer
verfasst von
Feng Xu
Zhigang Cai
Beizheng Xu
Jian Song
Haiyan Liu
Xuanmei Li
Aibing Deng
Xiaotang Wu
Jun Chen
Publikationsdatum
08.01.2021
Verlag
Springer London
Erschienen in
Lasers in Medical Science / Ausgabe 1/2022
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-020-03222-9